Abstract
Current data about the role of adamantanes and neuraminidase inhibitors (NIs) in the chemoprophylaxis against influenza viruses were reviewed. We found significant evidence favouring the role of NIs in the chemoprophylaxis of influenza. Awareness and prudent use are necessary, due to recent evidence of gradually increasing resistance of several influenza strains to these agents. On the other hand, the role of adamantanes appears to have decreased over the last decade. Both pre-pandemic and the novel pandemic A/H1N1 2009 strains exhibited either increasing rates of resistance or no susceptibility to adamantanes. Adamantanes currently only have a theoretical role in influenza chemoprophylaxis given the likelihood of the occurrence of an epidemic due to a susceptible strain. In conclusion, changes in antiviral susceptibility will affect future guidance in prophylaxis against influenza. Further investigation of novel medications with new mechanisms of action is important in this regard. Meanwhile, implementing strategies to conserve our current antivirals is necessary.
Keywords: Influenza, antivirals, chemoprophylaxis, adamantanes, neuraminidase inhibitors
Current Medicinal Chemistry
Title:Antivirals Used for Influenza Chemoprophylaxis
Volume: 19 Issue: 35
Author(s): S. Tsiodras, G. Nikolopoulos and S. Bonovas
Affiliation:
Keywords: Influenza, antivirals, chemoprophylaxis, adamantanes, neuraminidase inhibitors
Abstract: Current data about the role of adamantanes and neuraminidase inhibitors (NIs) in the chemoprophylaxis against influenza viruses were reviewed. We found significant evidence favouring the role of NIs in the chemoprophylaxis of influenza. Awareness and prudent use are necessary, due to recent evidence of gradually increasing resistance of several influenza strains to these agents. On the other hand, the role of adamantanes appears to have decreased over the last decade. Both pre-pandemic and the novel pandemic A/H1N1 2009 strains exhibited either increasing rates of resistance or no susceptibility to adamantanes. Adamantanes currently only have a theoretical role in influenza chemoprophylaxis given the likelihood of the occurrence of an epidemic due to a susceptible strain. In conclusion, changes in antiviral susceptibility will affect future guidance in prophylaxis against influenza. Further investigation of novel medications with new mechanisms of action is important in this regard. Meanwhile, implementing strategies to conserve our current antivirals is necessary.
Export Options
About this article
Cite this article as:
Tsiodras S., Nikolopoulos G. and Bonovas S., Antivirals Used for Influenza Chemoprophylaxis, Current Medicinal Chemistry 2012; 19 (35) . https://dx.doi.org/10.2174/0929867311209065947
DOI https://dx.doi.org/10.2174/0929867311209065947 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Design, Synthesis and Biological Evaluation of Ligands Selective for the Melanocortin-3 Receptor
Current Topics in Medicinal Chemistry Plasticity in Uterine Innervation: State of the Art
Current Protein & Peptide Science Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Neurogenic Drugs and Compounds to Treat CNS Diseases and Disorders
Central Nervous System Agents in Medicinal Chemistry Conference Report: The American Association for the Advancement of Science (AAAS), 180th Annual Meeting Chicago, IL, USA Feb 13-17, 2014 “Meeting Global Challenges: Discoveries & Innovation”
CNS & Neurological Disorders - Drug Targets Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design A Potential MRI Agent and an Anticancer Drug Encapsulated within CPMV Virus-Like Particles
Combinatorial Chemistry & High Throughput Screening Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Converging Perturbed Microvasculature and Microglial Clusters Characterize Alzheimer Disease Brain
Current Alzheimer Research Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research